Major cardiovascular outcome trials (EMPA-REG OUTCOME,[19] DECLARE-TIMI 58,[21] CANVAS[22] and CREDENCE[23]) have established the cardiorenal benefits of SGLT2 inhibitors in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.